SCHEMBL5032679

SCHEMBL5032679

CCOC(=O)c1csc(N(C(=O)c2ccccc2Cl)c2ccc(OC)c(OC)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 5/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
ABCB1 P08183 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 1/20 0.41
HSP90AA1 P07900 1/20 0.40
DHODH Q02127 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ACR P10323 1/20 0.40
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
ANO1 Q5XXA6 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035872 0.90 LMNA (0.48) LMNANPSR1HSD17B10MAPTNPC1
SCHEMBL5032563 0.88 ALDH1A1 (0.47) LMNAMAPTALDH1A1SMN1; SMN2CES2
SCHEMBL5035190 0.87 MAPT (0.49) LMNANPSR1MAPTNPC1RAB9A
SCHEMBL5039139 0.86 SMN1; SMN2 (0.40) LMNANPSR1HSD17B10MAPTRAB9A
SCHEMBL5032680 0.85 CES2 (0.41) LMNAMAPTALDH1A1HSP90AA1SMN1; SMN2
SCHEMBL5032672 0.84 TLR7 (0.40) LMNANPSR1MAPTNPC1RAB9A
SCHEMBL5035133 0.82 HPGD (0.47) LMNANPSR1HSD17B10MAPTALDH1A1
SCHEMBL5032534 0.82 NPC1 (0.44) HSD17B10NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL27643379 0.81 ALDH1A1 (0.42) LMNAHSD17B10MAPTNPC1RAB9A
SCHEMBL27664673 0.81 NPC1 (0.41) LMNAHSD17B10MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
JP-2007513193-A 2007-05-24 JP claimed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP claimed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US claimed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 LMNA 4010/4885NPSR1 39/4885HSD17B10 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.